Effective treatment and prevention of recurrent urinary tract infections by using Cysto-aurin®, a Solidago virgaurea preparation

M.V. Shostak, F.I. Kostyev, E.I. Lukinyuk

Abstract


We conducted a study of clinical and laboratory efficacy, as well as evaluated the effect on the quality of life of intermittent therapy with Cysto-aurin drug in 96 patients with recurrent urinary tract infection (UTI). After receiving an informed consent, the patients were divided into three statistically homogeneous groups. During the treatment, in all groups we used the strategy of behavioral therapy and postcoital prevention. Patients of group A additionally received Cysto-aurin 1 tablet qid by courses of 15 days in raw each month for 6 months, group B — the same drug for 2 tablets bid for 15 days in raw each month for 6 months, group C (comparison group) did not receive any special therapy. During the study, the data were obtained indicating a reliable decrease in the number of UTI relapses in groups A and B by 92.3 and 73.3 % within 6 months of treatment, depending on the frequency of drug administration. Analysis of the influence of the study drug on laboratory manifestations of recurrent UTI showed a positive effect of the intermittent treatment regimen on pyuria, a reduction in pro-inflammatory activity, and a statistically significant decrease of inflammation in the urinary system. Leukocyturia reduction in patients taking the drug was 73.4 and 44.6 %, i.e. 3.7 and 1.8 times lower than baseline, respectively. There was no statistically significant dynamics during the treatment among the patients of group C. A discrete and quantitative assessment of the impact of study drug on bacteriuria showed a clinically and statistically significant bacteriostatic effect of Cysto-aurin, both during the drug treatment in groups A and B (reduction by 41.0 and 27.6 %, respectively) and the prospective 6-month follow-up (by 30.3 and 18.0 %, respectively), which is an important confirmation of the effect of the drug on the microbial persistence in the urinary system. While structuring the antibacterial effect against clinically significant uropathogens, it was confirmed the reduction of E.coli strains by 61.1 and 31.9 %, Klebsiella pneumoniae — by 33.1 and 17.1 %, P.mirabilis — by 19.1 and 12.9 %, P.aeruginosa — by 21.1 and 14.1 %, Candida spp. — by 19.4 and 14.5 %, respectively. Evaluation of the effect of the study drug on the severity of recurrent chronic cystitis symptoms (UTI Symptoms Assessment) showed a significant decrease in the severity of key clinical symptomatic complexes of recurrent UTI: frequency (by 48.3 % in both groups), urgency (59.8 and 30.1 %), pain and burning (42.6 and 30.2 %), incomplete emptying of the bladder (53.8 and 30.9 %), as well as the integral indicator of clinical manifestations of pathology (24.7 and 39.2 %, respectively). The dynamics of health-related quality of life indicators (Short Form-36 score) when taking the study drug demonstrated a statistically significant induction of key quality-of-life domains for patients with recurrent UTI: mental health (33.4 vs. 32.5 %) and cumulative overall quality of life (19.6 against 14.6 %, respectively).

Keywords


urinary tract infections; recurrent cystitis; recurrent urinary tract infection; cystitis; goldenrod; Solidago virgaurea; prevention of cystitis; Cysto-aurin

References


Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. Nat Rev Microbiol. 2015 May;13(5):269-84. doi: 10.1038/nrmicro3432.

Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13. 2011 Apr;(169):1-38.

Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol. 2005 Apr;173(4):1281-7. doi: 10.1097/01.ju.0000155596.98780.82.

European Association of Urology. Guidelines on Urological Infections. 2015. Available from: http://uroweb.org/guideline/urological-infections/

Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J. 2011 Oct;5(5):316-22. doi: 10.5489/cuaj.11214.

Grimes CL, Lukacz ES. Urinary tract infections. Female Pelvic Med Reconstr Surg. 2011 Nov;17(6):272-8. doi: 10.1097/SPV.0b013e318237b99d.

Glover M, Moreira CG, Sperandio V, Zimmern P. Recurrent urinary tract infections in healthy and nonpregnant women. Urol Sci. 2014 Mar;25(1):1-8. doi: 10.1016/j.urols.2013.11.007.

van der Starre WE, van Nieuwkoop C, Paltansing S, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. 2011 Mar;66(3):650-6. doi: 10.1093/jac/dkq465.

Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 Mar;28(1):1-13. doi: 10.1016/j.idc.2013.09.003.

Ejrnæs К. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Dan Med Bull. 2011 Apr;58(4):B4187.

Dwyer PL, O'Reilly M. Recurrent urinary tract infection in the female. Curr Opin Obstet Gynecol. 2002 Oct;14(5):537-43.

Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000 Nov;10(8):509-15.

Veitch NC, Michael Smith M, Authors, Baxter IA, editor. Herbal Medicines. 4th edition. Pharmaceutical Press; 2013. 912 p.

European Medicines Agency. Assessment report on Solidago virgaurea L. herba. European Medicines Agency; 2008. 31 p.

Melzig MF. Goldenrod--a classical exponent in the urological phytotherapy. Wien Med Wochenschr. 2004 Nov;154(21-22):523-7. (in German).

Kołodziej B, Kowalski K, Kędzia B. Antibacterial and antimutagenic activity of extracts aboveground parts of three Solidago species: Solidago virgaurea L., Solidago canadensis L. and Solidago gigantea Ait. Journal of Medicinal Plants Research. 2011;5(31):6770-6779. doi: 10.5897/JMPR11.1098.

Laurençon L, Sarrazin E, Chevalier M, Prêcheur I, Herbette G, Fernandez X. Triterpenoid saponins from the aerial parts of Solidago virgaurea alpestris with inhibiting activity of Candida albicans yeast-hyphal conversion. Phytochemistry. 2013 Feb;86:103-11. doi: 10.1016/j.phytochem.2012.10.004.

Starks CM, Williams RB, Goering MG, et al. Antibacterial clerodane diterpenes from Goldenrod (Solidago virgaurea). Phytochemistry. 2010 Jan;71(1):104-9. doi: 10.1016/j.phytochem.2009.09.032.

Deng Y, Zhao Y, Padilla-Zakour O, Yang G. Polyphenols, antioxidant and antimicrobial activities of leaf and bark extracts of Solidago canadensis L. Industrial Crops and Products. 2015;74:803-809. doi: 10.1016/j.indcrop.2015.06.014.

Brantner A. The antimicrobial activity of Solidago-containing phytourologica. Drogen-report. 1999;12:27-28.

Thiem B, Goślińska O. Antimicrobial activity of Solidago virgaurea L. from in vitro cultures. Fitoterapia. 2002 Oct;73(6):514-6.

Strehl E, Schneider W, Elstner EF. Inhibition of dihydrofolate reductase activity by alcoholic extracts from Fraxinus excelsior, Populus tremula and Solidago virgaurea. Arzneimittelforschung. 1995 Feb;45(2):172-3.

Kalemba D. Constituents and biological activity of the essential oils of some Solidago and Artemisia species. Scientific Papers Technical University of Lodz. 2000; 857:1-118.

Pepeljnjak S, Kustrak D, Vukusic I. Investigation of the antimycotic activity of Solidago virgaurea and Solidago gigantea extracts. Pharm. Pharmacol Lett. 1998; 8: 85-86.

Laurençon L, Sarrazin E, Chevalier M, Prêcheur I, Herbette G, Fernandez X. Triterpenoid saponins from the aerial parts of Solidago virgaurea alpestris with inhibiting activity of Candida albicans yeasthyphal conversion. Phytochemistry. 2013 Feb;86:103-11. doi: 10.1016/j.phytochem.2012.10.004.

Melzig MF, Löser B, Bader G, Papsdorf G. Echtes Goldenrutenkraut als entzündungshemmende Droge. Z Phytother. 2000; 21: 67-70.

Meyer B, Schneider W, Elstner EF. Antioxidative properties of alcoholic extracts from Fraxinus excelsior, Populus tremula and Solidago virgaurea. Arzneimittelforschung. 1995 Feb;45(2):174-6.

Plohmann B, Bader G, Hiller K, Franz G. Immunomodulatory and antitumoral effects of triterpenoid saponins. Pharmazie. 1997 Dec;52(12):953-7.

Plohmann B, Franz G, Bader G, Hiller K. Immunmodulatorische und antitumorale Aktivität von Triterpensaponinen aus Solidago virgaurea L. Drogenreport. 1999;12:29-30. (in German).

Choi SZ, Choi SU, Bae SY, Pyo Sn, Lee KR. Immunobiological activity of a new benzyl benzoate from the aerial part sof Solidago virgaurea var. gigantean. Arch Pharm Res. 2005 Jan;28(1):49-54.

Westendorf J, Vahlensieck W. Spasmolytische und kontraktile Einflüsse eines pflanzlichen Kombinations-präparates auf die glatte Muskulatur des isolierten Meerschweinchendarms. ArzneimForsch/Drug Res. 1981;31:40-43.

Metzner J, Hirschelmann R, Hiller K. Antiphlogistische und analgetische Wirkungen von Leiocarposid, einem phenolischen Bisglucosid aus Solidago virgaurea L. Pharmazie. 1984;39: 869-870.

Sampson JH, Phillipson JD, Bowery NG, O'Neill MJ, Houston JG, Lewis JA. Ethnomedicinally selected plants as sources of potential analgesic compounds: indication of in vitro biological activity in receptor binding assays. Phytother Res. 2000 Feb;14(1):24-9.

Melzig MF. New aspects for understanding the mechanism of the aquaretic effects of birch leaves and goldenrod. Zeitschrift fur Phytotherapie. 2000;21(4):193-196. (in German).

Brantner A. The antimicrobial activity of Solidago-containing phytourologica. Drogen-report. 1999;12:27-28.

Thiem B, Goślińska O. Antimicrobial activity of Solidago virgaurea L. from in vitro cultures. Fitoterapia. 2002 Oct;73(6):514-6.

Strehl E, Schneider W, Elstner EF. Inhibition of dihydrofolate reductase activity by alcoholic extracts from Fraxinus excelsior, Populus tremula and Solidago virgaurea. Arzneimittelforschung. 1995 Feb;45(2):172-3.

Schakau D. Solidago Steiner® Tabletten. Solidago Steiner® Lösung und Harntee Steiner® Portfolio-Schulung. Januar, 2014.

Frumenzio E, Maglia D, Salvini E, at al. Role of phytotherapy associated with antibiotic prophylaxis in female patients with recurrent urinary tract infections. Arch Ital Urol Androl. 2013 Dec 31;85(4):197-9. doi: 10.4081/aiua.2013.4.197.




DOI: https://doi.org/10.22141/2307-1257.7.3.2018.140201

Copyright (c) 2018 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта